Wearable DHTs Demonstrate Meaningful Treatment Benefits for Patients with Cancer Cachexia

Overview

Pfizer partnered with ActiGraph to use wearable digital health technology to demonstrate a robust treatment benefit for patients with cancer cachexia in their phase 2 clinical trial (NCT05546476), providing meaningful evidence of treatment efficacy.

Read the full case study to learn how wearable-derived digital measures can:

• Provide objective evidence on the real-world impact of your new medical product on patients’ everyday lives
• Substantiate the evidential package with regulators, payers, and clinicians